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to IABP.
CONCLUSIONS This is the largest and the most contemporary study
on the use of hemodynamic support which demonstrates signiﬁcantly
reduced mortality and complications with PVADs when compared to
IABP in patients undergoing PCI and this effect is largely driven by the
improved outcomes in non-AMI and non-cardiogenic shock patients.
CATEGORIES CORONARY: Hemodynamic Support and Cardiogenic
Shock
KEYWORDS Mechanical circulatory support, Outcomes, Percuta-
neous coronary intervention
TCT-193
Emergent versus Elective Impella Placement and Impact on In-hospital
Outcomes-A Single Center Registry
Tae Yang,1 Mohamad Lazkani,1 Divya Ratan Verma,2 Hoang Nguyen,1
Shishir Murarka,3 Ashish Pershad4
1Banner University Medical Center, Phoenix, AZ; 2University of Utah
School of Medicine, Salt Lake City, UT; 3Banner Good Samaritan
Medical Center, Phoenix, AZ; 4Banner University Medical Center
Phoenix, Phoenix, AZ
BACKGROUND Impella (Abiomed Inc, Danvers, Mass) is a percuta-
neous left ventricular assist device used in the setting of high-risk
coronary intervention, cardiogenic shock and ablation procedures.
METHODS This is a single center study evaluating the use of Impella
in high-risk patients undergoing PCI. Impella use was classiﬁed as
‘elective’ in patients who were identiﬁed to be high-risk or in shock
prior to the procedure (Group 1, N¼ 129). Patients who received an
Impella as a result of an acute hemodynamic compromise or proce-
dural complication were classiﬁed as ‘emergent’ (Group 2, N¼ 57). The
primary endpoint was a composite MACE of in hospital mortality;
vascular complications and BARC deﬁned bleeding.
RESULTS Between 2010 and 2014, 187 high-risk patients underwent
Impella placement. The baseline demographics of both groups were
similar (Fig 1). The mean age was 67.5 years (p¼ns). The mean ejection
fraction was 28.3% (p¼ns). Elective Impella use (group 1) was
associated with more complete revascularization (2.3 vs 1.3 stents,
p<0.001), successful weaning and explant of Impella at end of
procedure (79% vs 10%, p<0.001) and successful hemostasis with
perclose in preclose fashion (81% vs 8%, p<0.001). The MACE rate
in Group 1 was 24% v/s 67% in Group 2 (p<0.001) (Table 1). The
drivers of this difference in MACE were in-hospital mortality (9% v/s
49%; p<0.001) and need for more blood transfusions in the
emergent group (1.3% v/s 2.9;p¼0.009). In multivariate analysis,
independent predictors of in hospital MACE events were emergent
Impella placement (OR 6.14, p<0.001), baseline ejection fraction and
removal of Impella at the end of the procedure (Fig 1).Outcomes Elective Emergent p-valueMACE 24 % (32) 67 % (41) <0.001Any Bleeding 23 % (30) 34 % (21) 0.09BARC major or life
threatening
bleeding15 % (19) 31 % (19) 0.48In-hospital death 9 % (12) 49 % (30) <0.001Vascular
Complications15 % (20) 16 % (10) 0.84Units of PRBCs infused 1.3  3.7 2.9  4.6 0.009
Bleeding at implant
site8 % (11) 15 % (9) 0.18Duration of procedure
(minutes  SD)
143  60 113  48 0.001Median length of stay
(Days  SD)
6  9.2 5  11 0.88CONCLUSIONS The real world use of the Impella mimics use in the
PROTECT 2 trial with similar baseline demographics and ejection
fraction. The elective use is largely in the setting of HRPCI whereas
the emergent use is largely in the setting of cardiogenic shock. In
hospital mortality and MACE in the emergent setting remain very high
whereas in the elective setting especially with early device explant,
the in-hospital mortality and MACE rates are low.
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BACKGROUND IABP is a widely used circulatory support device. The
IABP-SHOCK II trial (2012) showed that IABP did not improve 30-day
mortality. US and European guidelines have subsequently revised
their recommendations for IABP from class I to IIa and IIb, respec-
tively. Despite limited evidence, peripheral VA-ECMO is an estab-
lished treatment for refractory cardiogenic shock (CS). Current
guidelines have a IIb recommendation for use. The aim of this retro-
spective, observational analysis was to study the contemporary usage
patterns and outcomes of IABP, as well as to understand our early
experience with VA-ECMO in patients who have initially received an
IABP, at a single center.
METHODS From January 2010 to September 2014, we retrospec-
tively analyzed the Cardiac Catheterization database at Liverpool
Hospital, Sydney, for consecutive patients receiving an IABP,
including those who subsequently required VA-ECMO during the
same admission.
RESULTS Among 219 patients, who received a total of 222 IABP in-
sertions (mean age 65.911.8 years, range 23.1-91.4 years), 49 (22%)
were women; 38 (17%) had diabetes mellitus; 35 (16%) had left main
stenosis >70%; 29 (13%) were administered a GPIIbIIIa antagonist; 60
(27.4%) died during hospitalization. The 7.5Fr 40cc Sensation cath-
eter (Maquet, USA) was most commonly utilized (146 cases, 65.7%).
Mean dwell time was 46.143.7 hours (range 0.3–240 hours). Com-
plications occurred in 9 cases (2 severe access site bleeding requiring
transfusion, 1 minor access site bleeding, 4 leg ischemia, 1 access
related sepsis,1 IABP related mortality). CS was the commonest
indication and had high in-hospital mortality (46.3%). A total of 7
patients required VA-ECMO (mean age 64.79.6 years, range 49 to
75.2 years), 2 were women; 4 had diabetes mellitus. VA-ECMO was
initiated before left main stenting in 2 cases, and after revasculari-
zation in the others. IABP was left in situ in 3 patients. VA-ECMO was
